Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall
On the operating side, Ebitda jumped to Rs 128 crore from Rs 37 crore, while margin expanded to 17.8% from 5.3%.
Wockhardt Ltd. swung back to profit in the quarter ended December 2024, with a bottom line of Rs 14 crore, according to an exchange filing on Friday.
The Mumbai-based company had, in the year-ago quarter, logged a net loss of Rs 83 crore.
The pharmaceutical maker's revenue rose 2.9% to Rs 721 crore in the third quarter of the ongoing financial year, compared to Rs 701 crore in the same period last year. On the operating side, Ebitda jumped 85% to Rs 96 crore from Rs 52 crore, while margin expanded to 13.3% from 7.4%.
Wockhardt Q3 Results (Consolidated YoY)
Revenue up 2.9% at Rs 721 crore versus Rs 701 crore.
Net profit at Rs 14 crore versus loss of Rs 83 crore
Ebitda at 84.6% at Rs 96 crore versus Rs 52 crore.
Margin at 13.3% versus 7.4%.
Wockhardt's share price was trading 2% higher at Rs 1,618 apiece at 2:15 p.m. on the NSE, compared to a 0.39% drop in the benchmark Nifty 50. A day prior, the stock spiked 1.5% after the results.
The stock has risen 262.05% in the last 12 months. Total traded volume so far in the day stood at 0.54 times its 30-day average. The relative strength index was at 58.81.
